Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Characterization and clinical implications of CpG island methylator phenotypes of resistant tumors.

Clinical epigenetics - 30 Jan 2026

Hou Fei, Zhou Xu, Huang Yu-E, Liu Haizhou, Yuan Mengqin, Chen Jiahao, Wang Quan, Jiang Wei

Abstract excerpt

BACKGROUND: Drug resistance, characterized by high heterogeneity and complex mechanisms, poses a significant challenge in cancer treatment. Stratifying resistant tumors into biologically and clinically meaningful subgroups can improve prognostic evaluation and help guide treatment decisions. However, the DNA methylation-based subtypes of resistant tumors have not yet been comprehensively characterized. RESULTS:...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CpG Islands
Share to DNA Methylation
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Glioma

Share to Neoplasms

Share to Phenotype

Share to Prognosis

Share to Temozolomide

Source

Open in PubMed Open full text

Identifiers

PMID: 41612430
DOI: 10.1186/s13148-026-02058-4
PMCID: PMC12933914

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Characterization and clinical implications of CpG island methylator phenotypes of resistant tumors.PMID 41612430Read ↗

Variations in DNA Repair Genes and Intratumoral Genetic Heterogeneity in Temozolomide-Resistant Glioblastoma.Semantic proximity Read ↗

Genome-wide DNA methylation analysis identifies potent CpG signature for temzolomide response in non-G-CIMP glioblastomas with unmethylated MGMT promoter: MGMT-dependent roles of GPR81.Semantic proximity Read ↗

Identification of Predictive DNA Methylation Biomarkers for Chemotherapy Response in Colorectal CancerSemantic proximity Read ↗

Distinct epigenetic shift in a subset of Glioma CpG island methylator phenotype (G-CIMP) during tumor recurrenceSemantic proximity Read ↗

A Distinct DNA Methylation Shift in a Subset of Glioma CpG Island Methylator Phenotypes during Tumor Recurrence.Semantic proximity Read ↗

Potent predictive CpG signature for temozolomide response in non-glioma-CpG island methylator phenotype glioblastomas with methylated MGMT promoter.Semantic proximity Read ↗

Effect of DNA methylation status on first-line anti-epidermal growth factor receptor treatment in patients with metastatic colorectal cancer.Semantic proximity Read ↗

Pharmacogenomic profiling reveals molecular features of chemotherapy resistance in IDH wild-type primary glioblastomaSemantic proximity Read ↗

Abnormal methylation characteristics predict chemoresistance and poor prognosis in advanced high-grade serous ovarian cancerSemantic proximity Read ↗

Whole-exome sequencing reveals potential mechanisms of drug resistance to FGFR3-TACC3 targeted therapy and subsequent drug selection: towards a personalized medicine.Semantic proximity Read ↗

Designing Effective Protein Lysine and Arginine Methyltransferase Inhibitors for Chemotherapeutic TargetingSemantic proximity Read ↗

Genome-wide DNA methylome analysis identifies methylation signatures associated with survival and drug resistance of ovarian cancersSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.